Manufacturing Systems, Single-Use

High Purity New England has launched its third facility, focused on single-use assemblies.

The past year of downstream processing has brought innovations in pH sensitive antibody purification, single-use fermentation separators, and more.

Flexible and efficient methods are needed for biopharmaceutical manufacturing.

Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.

The need for specialized skills in biopharmaceutical manufacturing requires workforce training.

Innovations aid efficient processing.

Fujifilm is expanding its R&D footprint at its California facility.

Disposable equipment components find use in small-volume aseptic biopharmaceutical manufacturing.

Large-scale single-use bioreactors prove successful as limits are tested.

Early control architecture decisions can impact a facility’s long-term growth, flexibility, and efficiency.

CPC’s MicroCNX Series Connectors provide an alternative to tube welding at small tubing sizes.

Thermo Fisher Scientific plans to expand its Nashville, Tenn., site by establishing a dedicated single-use technology manufacturing facility at the site, doubling capacity.

The benefits of single-use technologies for upstream viral-vector processes clearly outweigh their disadvantages.

Through the adoption of single-use technology, drug manufacturers have been able to adapt to the challenges posed by the COVID-19 pandemic.

NewAge Industries is adding cleanrooms at its Pennsylvania headquarters.

Through the acquisition, Avantor will have access to RIM’s Changzhou, China, facility, making it Avantor’s first single-use production plant in the AMEA region.

Lonza plans to invest approximately CHF 850 million (US$936 million) to build new state-of-the-art mammalian manufacturing facilities at its Visp, Switzerland, and Portsmouth, NH, sites.

Avantor plans to increase its single-use manufacturing footprint by 30% and double its cleanroom space in the US and Europe.

AkesoBio’s expanded manufacturing capacity, enabled by the addition of another Cytiva FlexFactory platform, will be used to meet current and future market needs in China as well as worldwide.

Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics for upstream bioprocessing capacity.

The innovation of single-use technologies is applicable early on in the manufacturing process.

The adoption of single-use technologies in fluid-handling systems helps streamline downstream bioprocessing operations.

The availability of materials is a critical factor when it comes to vaccine capacity.

The investments are expected to double Thermo Fisher’s manufacturing capacity while creating more than 1500 jobs at 11 manufacturing sites in the Americas, Europe, and Asia.

Cytiva’s new facility in Shrewsbury, MA will make equipment such as single-use bioreactors.